A d-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Clinical management of patients undergoing treatment of oropharyngeal candidiasis with azole antifungals can be impaired by azole resistance. High-level azole resistance is often caused by the overexpression of Candida albicans efflux pump Cdr1p. Inhibition of this pump therefore represents a target for combination therapies that reverse azole resistance. We assessed the therapeutic potential of the D-octapeptide derivative RC21v3, a Cdr1p inhibitor, in the treatment of murine oral candidiasis caused by either the azole-resistant C. albicans clinical isolate MML611 or its azole-susceptible parental strain MML610. RC21v3, fluconazole (FLC), or a combination of both drugs were administered orally to immunosuppressed ICR mice at 3, 24, and 27 h after oral inoculation with C. albicans. FLC protected the mice inoculated with MML610 from oral candidiasis, but was only partially effective in MML611-infected mice. The co-application of RC21v3 (0.02 μmol per dose) potentiated the therapeutic performance of FLC for mice infected with either strain. It caused a statistically significant decrease in C. albicans cfu isolated from the oral cavity of the infected mice and reduced oral lesions. RC21v3 also enhanced the therapeutic activity of itraconazole against MML611 infection. These results indicate that RC21v3 in combination with azoles has potential as a therapy against azole-resistant oral candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
Steinbach, W. J., Reedy, J. L., Cramer, R. A., Perfect, J. R., & Heitman, J. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1680 · Cited by 313
Genotypic Evolution of Azole Resistance Mechanisms in Sequential Candida albicans Isolates
Coste, A., Selmecki, A., Forche, A., Diogo, D., Bougnoux, M.-E., d'Enfert, C., Berman, J., & Sanglard, D. (2007) · Eukaryotic Cell · doi:10.1128/ec.00151-07 · Cited by 305 · cited 4×
“It has been shown that clinically significant azole resistance in C. albicans is accompanied by increased transcription of the CDR1 and CDR2 genes, encoding ATP-binding cassette transporters Cdr1p and Cdr2p (White, 1997; Coste et al., 2007).”
BackgroundInfluentialSynergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms
Uppuluri, P., Nett, J., Heitman, J., & Andes, D. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01397-07 · Cited by 228 · cited 1×
“It can also act indirectly because of the effects on the calcineurin pathway (Cannon et al., 2007; Steinbach et al., 2007; Sun et al., 2008; Uppuluri et al., 2008).”
BackgroundCandida albicans drug resistance—Another way to cope with stress
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Tanabe, K., Niimi, M., & Monk, B. C. (2007) · Microbiology · doi:10.1099/mic.0.2007/010405-0 · Cited by 208 · cited 1×
“It can also act indirectly because of the effects on the calcineurin pathway (Cannon et al., 2007; Steinbach et al., 2007; Sun et al., 2008; Uppuluri et al., 2008).”
BackgroundSelf-citation
Cited by
Kourtesi, C., Ball, A. R., Huang, Y.-Y., Jachak, S. M., Vera, D. M. A., Khondkar, P., Gibbons, S., Hamblin, M. R., & Tegos, G. P. (2013) · The Open Microbiology Journal · doi:10.2174/1874285801307010034 · Cited by 159
Targeting Efflux Pumps to Overcome Antifungal Drug Resistance
Holmes, A. R., Cardno, T. S., Strouse, J. J., Ivnitski-Steele, I., Keniya, M. V., Lackovic, K., Monk, B. C., Sklar, L. A., & Cannon, R. D. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0050 · Cited by 156
Self-citationMorschhäuser, J. (2016) · Journal of Microbiology · doi:10.1007/s12275-016-5628-4 · Cited by 118
Sasse, C., Dunkel, N., Schäfer, T., Schneider, S., Dierolf, F., Ohlsen, K., & Morschhäuser, J. (2012) · Molecular Microbiology · doi:10.1111/j.1365-2958.2012.08210.x · Cited by 93
“In investigations with serial isolates from different patients, both decreased and unaltered virulence of fluconazole-resistant strains were observed (Graybill et al., 1998; Schulz et al., 2011; Hayama et al., 2012).”
BackgroundCompetitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains
Popp, C., Hampe, I. A. I., Hertlein, T., Ohlsen, K., Rogers, P. D., & Morschhäuser, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00584-17 · Cited by 56
“albicans isolates with GOF mutations in MRR1 or TAC1 were also found to be less virulent than fluconazole-susceptible isolates from the same patients in mouse models of systemic or oral candidiasis (27, 28).”
Background
Metadata
- Authors
- Hayama, K., Ishibashi, H., Ishijima, S. A., Niimi, K., Tansho, S., Ono, Y., Monk, B. C., Holmes, A. R., Harding, D. R. K., Cannon, R. D., & Abe, S.
- Venue
- FEMS Microbiology Letters
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-01-16
- Volume
- 328
- Issue
- 2
- Pages
- 130-137
- ISSN
- 0378-1097 (ISSN-L)
- OpenAlex
- W2019857512
- Cited by
- 34
- References
- 6
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.